Vensana Capital

Vensana Capital invests in development and commercial stage companies within the medtech sector. Their primary focus areas include medical devices, diagnostics, data science, drug delivery, digital health, life science tools, and tech-enabled services. The firm typically makes investments ranging from $15 million to $50 million per company, allowing them to provide substantial support to their portfolio companies.

The firm seeks to partner with entrepreneurs who are dedicated to advancing healthcare solutions. Vensana Capital emphasizes the importance of innovation and market potential in its investment decisions, aiming to support companies that can significantly impact patient care and outcomes.

Vensana Capital has a diverse portfolio of companies, including:

• Abrus Bio: Focuses on innovative treatments.
• Alleviant Medical: Specializes in interventional heart failure technologies.
• Apella: Works on digitizing operating rooms.
• CVRx: Publicly traded company focused on heart disease solutions.
• Luna Diabetes: Develops automated insulin delivery solutions.
• SpyGlass Pharma: Engages in long-term drug delivery platforms for glaucoma patients.
• Vesper Medical: Acquired by Philips, focuses on image-guided therapy devices.
• Cartiva: Acquired, known for its innovative treatments.
• CV Ingenuity: Acquired, focused on cardiovascular solutions.
• Epix Therapeutics: Acquired, specializes in therapeutic innovations.
• Intact Vascular: Acquired, known for its vascular solutions.
• Personal Genome Diagnostics: Acquired, focuses on genomic solutions.
• PhaseBio Pharmaceuticals: IPO, specializes in biopharmaceuticals.
• Relievant Medsystems: Acquired, known for its pain management solutions.
• Senseonics: IPO, focuses on diabetes management solutions.
• Topera: Acquired, specializes in cardiac mapping technologies.
• Ulthera: Acquired, known for its aesthetic medical devices.
• Vertiflex: Acquired, focuses on spinal solutions.
• VytronUS: Acquired, specializes in cardiac imaging technologies.

Justin Klein, MD, JD: Co-founder and Managing Partner. He has extensive experience in healthcare investments and has led numerous successful deals in the medtech sector.

Kirk Nielsen: Co-founder and Managing Partner. He brings a wealth of knowledge in venture capital and has a strong background in healthcare innovation.

Amrinder Singh: Partner. He specializes in identifying and supporting early-stage healthcare companies.

Greg Banker: Partner. He has a background in operational roles within healthcare companies, providing valuable insights to portfolio firms.

Maria Berkman: Partner. She focuses on strategic investments in the medtech space, leveraging her experience in the industry.

Ross (Rusty) Segan: Venture Partner. He has a strong track record in healthcare investments and provides mentorship to portfolio companies.

To pitch to Vensana Capital, founders should use the contact form available on their website. A comprehensive pitch deck should include the business model, market analysis, and financial projections. The firm prefers to receive pitches through warm introductions, but direct submissions are also accepted.

Response times may vary, but founders can expect to hear back within a few weeks after submission.

Vensana Capital has established **Vensana Innovation (VI)**, an innovation engine dedicated to launching and building medtech companies. VI pairs capital with a dedicated team that provides technical, clinical, commercial, and business development expertise.

In recent months, Vensana Capital has highlighted significant developments within its portfolio. Notably, SpyGlass Pharma completed its IPO, marking a major milestone for the firm. Additionally, funding rounds for Ventaris Surgical and Apella have been announced, showcasing Vensana's active engagement with its portfolio companies.

Vensana Capital also co-chaired the Medtech Venture & Partnering Conference in 2021, further establishing its presence in the medtech investment community.